Atectura Breezhaler

Pays: Nouvelle-Zélande

Langue: anglais

Source: Medsafe (Medicines Safety Authority)

Ingrédients actifs:

Indacaterol acetate 173ug equivalent to indacaterol 150 µg; Mometasone furoate 80ug

Disponible depuis:

Novartis New Zealand Ltd

forme pharmaceutique:

Powder filled inhalation capsule

Composition:

Active: Indacaterol acetate 173ug equivalent to indacaterol 150 µg Mometasone furoate 80ug Excipient: Gelatin Printing ink, blue Lactose monohydrate

Type d'ordonnance:

Prescription

indications thérapeutiques:

Atectura breezhaler is indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older where use of a combination of long-acting beta2-agonist and inhaled corticosteroid is appropriate: · patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists or · patients not adequately controlled with long-acting beta2-agonists and low dose of inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists.

Descriptif du produit:

Package - Contents - Shelf Life: Blister pack, PA/Al/PVC/Al-polyamide-aluminium foil-polyvinylchloride/aluminium foil + inhaler - 10 capsules - 24 months from date of manufacture stored at or below 25°C protect from light and moisture - Blister pack, PA/Al/PVC/Al-polyamide-aluminium foil-polyvinylchloride/aluminium foil + inhaler - 30 capsules - 24 months from date of manufacture stored at or below 25°C protect from light and moisture

Date de l'autorisation:

2020-10-21